Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Shares Outstanding (2016 - 2025)

Sutro Biopharma's Shares Outstanding history spans 10 years, with the latest figure at $85.1 million for Q3 2025.

  • For Q3 2025, Shares Outstanding rose 3.28% year-over-year to $85.1 million; the TTM value through Sep 2025 reached $85.1 million, up 3.28%, while the annual FY2024 figure was $82.5 million, 35.27% up from the prior year.
  • Shares Outstanding for Q3 2025 was $85.1 million at Sutro Biopharma, roughly flat from $84.7 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $85.1 million in Q3 2025 and bottomed at $46.1 million in Q1 2021.
  • The 5-year median for Shares Outstanding is $60.5 million (2023), against an average of $63.1 million.
  • The largest YoY upside for Shares Outstanding was 98.49% in 2021 against a maximum downside of 1.26% in 2021.
  • A 5-year view of Shares Outstanding shows it stood at $46.3 million in 2021, then rose by 24.12% to $57.5 million in 2022, then grew by 6.1% to $61.0 million in 2023, then skyrocketed by 35.27% to $82.5 million in 2024, then grew by 3.12% to $85.1 million in 2025.
  • Per Business Quant, the three most recent readings for STRO's Shares Outstanding are $85.1 million (Q3 2025), $84.7 million (Q2 2025), and $84.3 million (Q1 2025).